Clovis Oncology is a biopharmaceutical company that specializes in developing anti-cancer agents for patients in the United States, Europe, and other parts of the world. The company is currently focused on three product candidates including Rociletinib, Rucaparib, and Lucitanib. Rociletinib is an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is being developed for the treatment of non-small cell lung cancer. Rucaparib is an oral inhibitor of poly polymerase that is in advanced clinical development for the treatment of ovarian cancer. Lastly, Lucitanib is an oral inhibitor of the tyrosine kinase and is in Phase II development for the treatment of breast and lung cancers.